ASCENTAGE (06855) granted 440,700 restricted share units in accordance with the Restricted Share Unit Plan for 2021.

ASCENTAGE (06855) announced that as of the date of this announcement, a total of 440,700 restricted share units (2021 awards) were granted to 453 selected individuals (2021 awardees) under the 2021 Restricted Share Unit Plan, who are employees of the company, equivalent to 440,700 shares (further grants in 2021). As of the date of this announcement, a total of 3,223,700 restricted share units (2022 awards) were granted to 251 selected individuals (2022 awardees) under the 2022 Restricted Share Unit Plan, equivalent to 3,223,700 shares (further grants in 2022), with (i) two non-executive directors (Dr. Wang Shaomeng and Dr. Lv Dazhong) being granted 31,858 restricted share units; (ii) six independent non-executive directors (Mr. Ye Changqing, Mr. Ren We, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu, and Dr. Marc E. Lippman) being granted 106,194 restricted share units; (iii) one senior management personnel of the company being granted 150,739 restricted share units; (iv) 241 other 2022 awardees who are employees of the company being granted 2,924,900 restricted share units; and (v) one service provider (a research, clinical trial, and academic expert advisor providing consultancy services to any member of the company in drug development and clinical trials in the company's daily and general business processes, in line with the long-term growth interests of the company) being granted 10,000 restricted share units. As of the date of this announcement, the company granted a total of 690,000 share options to 30 individuals (option grantee) under the terms of the Share Option Plan after the initial public offering, which can be used to subscribed to a total of 690,000 shares of the company's common stock when exercising the relevant share options, subject to acceptance by the option grantee, with (i) 31,858 share options granted to the two non-executive directors, Dr. Wang Shaomeng and Dr. Lv Dazhong; (ii) 106,194 share options granted to the six independent non-executive directors, Mr. Ye Changqing, Mr. Ren We, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu, and Dr. Marc E. Lippman; (iii) 50,641 share options granted to one senior management personnel of the company; and (iv) 501,400 share options granted to 21 option grantees who are employees of the company.